Gapping up
In reaction to strong earnings/guidance: ADBE +7.7%, FDX +3.9%, GAME +0.4%.
M&A news: LULU +2.6% (attributed to M&A story making the rounds), ACT +1.2% (Forest Labs and Actavis shareholders approve proposals related to Actavis' planned acquisition of Forest), MOVE +1.1% (continuation higher on M&A speculation), TMUS +0.7% (may purchase spectrum assets from smaller cos, according to reports), RHT +0.4% (to acquire eNovance for ~ EUR50 mln in cash and EUR20 mln in shares of RHT common stock).
Select Battery related names showing strength following positive blog mention: PLUG +1.6%, FCEL +1.3%.
Other news: INSM +30.3% (FDA granted Arikayce Breakthrough Therapy Designation for the treatment of adult patients with nontuberculous mycobacterial lung disease), NEWL +23.5% (NewLead Holdings Ltd. announces inappropriate issuance of NewLead's Shares by Ironridge), ETRM +21.1% (FDA Advisory Committee voted 6-2 to recommend approval of VBLOC vagal blocking therapy for the treatment of obesity), BBRY +6.5% (confirms upcoming AMZN app store partnership), APD +6.1% (confirms Seifi Ghasemi has been named its new chairman, president and chief executive officer), APD +5.9% (confirms Seifi Ghasemi has been named its new chairman, president and chief executive officer, effective July 1), AUMN +2.8% (to restart Velardena mining in July 2014), CNHI+2.6% (co's JV TurkTractor announced the opening of its second manufacturing plant in Erenler, raises production capacity to 50,000 tractors per year), ENB +1.9% (Northern Gateway Project received approval from the government of Canada), RDS.B +1.9% (wrapped up its sale of Woodside Petro, positive mention on Mad Money), RAD +1.7% (ahead of earnings tomorrow, peer WAG also was upgraded today), RDS.A +1.6% (same as RDS.B), CBI +1.4% (following 7% move lower yesterday), SUNE +1.4% (co reached a definitive agreement to acquire a 50% ownership stake in Silver Ridge Power from a subsidiary of The AES Corporation), CBI +1.4% (comments on 'misleading and inaccurate report'; reaffirms FY guidance, also upgraded to Buy from Neutral at DA Davidson), FLXN+1.3% (announces 'positive' topline results from Phase 2a pharmacokinetic trial with lead compound FX006), COV +1% (ongoing M&A speculation), UPS +1% (in sympathy with FDX earnings).
Analyst comments: MEET +16.6% (initiated with a Buy at Wunderlich), NMBL +4.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley), WAG +2.2% (upgraded to Overweight from Equal Weight at Barclays), CECO +2.2% (upgraded to Equal Weight from Underweight at First Analysis), DMND +1.9% (upgraded to Buy from Hold at KeyBanc Capital Mkts), IPI +1.8% (initiated with a Overweight at Piper Jaffray), ACT +1.2% (resumed with a Overweight at Morgan Stanley), CSCO +1.1% (initiated with a Overweight at Morgan Stanley), TSN +1.1% (upgraded to Outperform from Mkt Perform at BMO Capital Mkts, SDPI +0.9% (initiated with a Buy at ROTH Capital), CGEN +0.8% (initiated with a Mkt Outperform at JMP Securities), FIVE +0.8% (initiated with a Outperform at Wedbush), DTV +0.6% (upgraded to Buy from Neutral at Buckingham Research)
In reaction to strong earnings/guidance: ADBE +7.7%, FDX +3.9%, GAME +0.4%.
M&A news: LULU +2.6% (attributed to M&A story making the rounds), ACT +1.2% (Forest Labs and Actavis shareholders approve proposals related to Actavis' planned acquisition of Forest), MOVE +1.1% (continuation higher on M&A speculation), TMUS +0.7% (may purchase spectrum assets from smaller cos, according to reports), RHT +0.4% (to acquire eNovance for ~ EUR50 mln in cash and EUR20 mln in shares of RHT common stock).
Select Battery related names showing strength following positive blog mention: PLUG +1.6%, FCEL +1.3%.
Other news: INSM +30.3% (FDA granted Arikayce Breakthrough Therapy Designation for the treatment of adult patients with nontuberculous mycobacterial lung disease), NEWL +23.5% (NewLead Holdings Ltd. announces inappropriate issuance of NewLead's Shares by Ironridge), ETRM +21.1% (FDA Advisory Committee voted 6-2 to recommend approval of VBLOC vagal blocking therapy for the treatment of obesity), BBRY +6.5% (confirms upcoming AMZN app store partnership), APD +6.1% (confirms Seifi Ghasemi has been named its new chairman, president and chief executive officer), APD +5.9% (confirms Seifi Ghasemi has been named its new chairman, president and chief executive officer, effective July 1), AUMN +2.8% (to restart Velardena mining in July 2014), CNHI+2.6% (co's JV TurkTractor announced the opening of its second manufacturing plant in Erenler, raises production capacity to 50,000 tractors per year), ENB +1.9% (Northern Gateway Project received approval from the government of Canada), RDS.B +1.9% (wrapped up its sale of Woodside Petro, positive mention on Mad Money), RAD +1.7% (ahead of earnings tomorrow, peer WAG also was upgraded today), RDS.A +1.6% (same as RDS.B), CBI +1.4% (following 7% move lower yesterday), SUNE +1.4% (co reached a definitive agreement to acquire a 50% ownership stake in Silver Ridge Power from a subsidiary of The AES Corporation), CBI +1.4% (comments on 'misleading and inaccurate report'; reaffirms FY guidance, also upgraded to Buy from Neutral at DA Davidson), FLXN+1.3% (announces 'positive' topline results from Phase 2a pharmacokinetic trial with lead compound FX006), COV +1% (ongoing M&A speculation), UPS +1% (in sympathy with FDX earnings).
Analyst comments: MEET +16.6% (initiated with a Buy at Wunderlich), NMBL +4.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley), WAG +2.2% (upgraded to Overweight from Equal Weight at Barclays), CECO +2.2% (upgraded to Equal Weight from Underweight at First Analysis), DMND +1.9% (upgraded to Buy from Hold at KeyBanc Capital Mkts), IPI +1.8% (initiated with a Overweight at Piper Jaffray), ACT +1.2% (resumed with a Overweight at Morgan Stanley), CSCO +1.1% (initiated with a Overweight at Morgan Stanley), TSN +1.1% (upgraded to Outperform from Mkt Perform at BMO Capital Mkts, SDPI +0.9% (initiated with a Buy at ROTH Capital), CGEN +0.8% (initiated with a Mkt Outperform at JMP Securities), FIVE +0.8% (initiated with a Outperform at Wedbush), DTV +0.6% (upgraded to Buy from Neutral at Buckingham Research)